At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 267 enrolled
Drug / intervention
bucindolol hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
In Brief
A Phase 2 clinical trial evaluating bucindolol hydrochloride, metoprolol succinate, and 1 other intervention for Current or Recent History of Atrial Fibrillation. Completed, enrolled 267 participants across 97 sites in 6 countries.
Detailed Summary
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Hungary, Netherlands, Poland, Serbia, United States
CollaboratorsMedtronic
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartApr 2014
Primary CompletionDec 2017
TodayJul 2026
First PostedOct 28, 2013
Enrollment StartApr 1, 2014
Primary CompletionDec 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.7 years ago
Interventions
bucindolol hydrochloridedrug
metoprolol succinatedrug
Placebo oral capsuleother